Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors
- Resource Type
- Article
- Authors
- Ripamonti, Alessia; Aroldi, Andrea; Cocito, Federica; Guerra, Luca; Monaco, Lavinia; Granelli, Bianca Maria; Mussolin, Lara; Gambacorti-Passerini, Carlo
- Source
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p4474-4474, 1p
- Subject
- Language
- ISSN
- 00064971; 15280020
Introduction:Both aggressive T and B cell lymphoma may harbour Anaplastic Lymphoma Kinase (ALK) translocations: ALK+ Anaplastic Large Cell lymphoma (ALCL) offer a good outcome with first line therapy with 5-year survival of 79%, but relapses occur in half of the patients (pts) and salvage therapy still represents a challenge for clinicians; ALK+ large B cell lymphoma (LBCL) are very rare cases but with dismal prognosis. In addition other hematologic neoplasms can be caused by ALK fusions.